Ipsen (LTS:0MH6) Moat Score: 6/10 (As of Jul. 09, 2026)


LTS:0MH6 Ipsen SA LTS:0MH6
94 GF Score
Price €165.50
GF Value €133.79
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Ipsen Moat Score?

Ipsen LTS:0MH6 -1.78% 94 Moat Score is 6 as of Jul. 09, 2026. GuruFocus rates LTS:0MH6 with a GF Score™ of 94/100 and a GF Value™ of €133.79 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Ipsen ranks better than 97.09% on this metric.

Ipsen has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Ipsen has Narrow Moat: Ipsen SA has a strong narrow moat with its valuable pharmaceutical patents and consistent R&D capabilities. It benefits from brand strength in specific therapeutic areas but lacks the broad market dominance required for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Ipsen might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Ipsen  (LTS:0MH6) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Ipsen Moat Score Related Terms

LTS:0MH6 vs ZTS, UTHR, VTRS: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ipsen's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ipsen Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ipsen's Moat Score distribution charts can be found below:

* The bar in red indicates where Ipsen's Moat Score falls into.


LTS:0MH6
94GF Score
Ipsen SA LTS:0MH6
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Ipsen (LTS:0MH6) has a Moat Score of 6 as of Jul. 09, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Ipsen ranks #30 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Ipsen's Moat Score too high?
Ipsen's current Moat Score is 6. Based on the distribution chart, Ipsen ranks #30 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ipsen has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ipsen's Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ipsen ranks #30 out of 1031 companies for Moat Score. This places Ipsen in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Ipsen's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipsen stock overvalued right now?
Based on GuruFocus' analysis, Ipsen (LTS:0MH6) is currently considered Modestly Overvalued. The stock's GF Value™ is €133.79, compared to a current price of €165.50 — trading 23.7% above its estimated fair value. The current Moat Score is 6. Ipsen's overall GF Score™ is 94/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Ipsen (LTS:0MH6), the current Moat Score is 6 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ipsen (LTS:0MH6) Overvalued in 2026?

Based on GuruFocus' analysis, Ipsen stock appears to be overvalued. The current stock price of €165.50 is trading 23.7% above its estimated GF Value™ of €133.79. GuruFocus considers Ipsen to be Modestly Overvalued.

Key valuation signals for LTS:0MH6:

  • Moat Score: 6
  • GF Value™: €133.79 vs. price of €165.50 (23.7% above fair value)
  • GF Score™: 94/100 with 7 warning signs

No single metric tells the full story. See the LTS:0MH6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ipsen Business Description

Address 70 rue Balard, Paris, FRA, 75015
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
94GF Score

Get the complete analysis for LTS:0MH6

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€165.50
Price
€133.79
GF Value